Not Yet RecruitingPhase 2

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

China90 participantsStarted 2025-07

Plain-language summary

To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent obtained
✓. Age 18-70 years (inclusive)
✓. Candidates for hip/knee arthroplasty
✓. No DVT on pre-op venous ultrasound
✓. Screening Hb 80-110 g/L (no transfusion indication) - 6. Commitment to effective contraception

Exclusion criteria

✕. Hypersensitivity to the investigational product or any of its components
✕. Any other condition causing chronic anemia
✕. Coagulopathy or unstable anticoagulant dosing during screening
✕. Any of the following laboratory abnormalities at screening:
✕. Serum albumin \<35 g/L
✕. ALT or AST \>3×ULN
✕. Active infections or carrier status including:
✕. Acute joint injury with active trauma or infection at screening

What they're measuring

Change from baseline in hemoglobin

Timeframe: Day 8，Day 15，Day 29

Trial details

NCT IDNCT07007936

SponsorShenyang Sunshine Pharmaceutical Co., LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-04

Contact for this trial

Professor Lin, Ph.D

010-88324516 rmyyllwyh@163.com

View on ClinicalTrials.gov More Postoperative Anemia trials